The veterinary-grade rabies antigen concentrate (API) is handled as an inactivated whole virus or recombinant glycoprotein intermediate that is thawed at 2–8 °C over 12–18 h and clarified through a 0.45 µm sterile polyethersulfone membrane before inline blending with aluminium hydroxide gel. The final injectable formulation is adjusted to a minimum release potency of 1.0 IU per dose against the reference preparation used in Ph. Eur. monograph 0451 or the potency protocol referenced in 9 CFR 113.209. A final aluminium concentration of 1.0–2.0 mg per dose is maintained, because higher Al(III) loads shift phosphate-buffered saline equilibrium and can lower pH to 6.4–6.6 during 24-month shelf storage. The blend is mixed in a closed stainless-steel vessel at 2–8 °C with a top-mounted agitator; continuous low-shear mixing at 80–120 rpm prevents gel sedimentation without shearing the adsorbed antigen complex.

Release testing includes bacterial endotoxin by Ph. Eur. 2.6.14 or USP <85>, sterility by Ph. Eur. 2.6.1, and virus titer by cell culture infectivity in BHK-21 or Vero cell substrate. Inactivation completeness is verified by blind passage in the same cell line with no cytopathic effect over three passages. Multi-dose vials for livestock require antimicrobial preservation; thiomersal at 0.01% w/v or 2-phenoxyethanol at 0.5% v/v is added before final volume adjustment, with antimicrobial effectiveness testing following USP <51> or Ph. Eur. 5.1.3. The finished suspension is filled into Type I glass vials on a rotary piston line at 4±2 °C; filling needles with inner diameter 1.0 mm and slow stroke settings prevent galling of the aluminium gel. Frozen transport is prohibited; one freeze-thaw cycle at -20 °C causes gel aggregation and a potency loss of 0.3–0.7 log10 IU per dose depending on residual phosphate content. Contact surfaces must be rinsed to remove quaternary ammonium disinfectants; residual levels above 0.5 ppm in rinse water inactivate the enveloped virus and reduce release potency.

What Governs Vaccine Release from Fishmeal-Polymer Oral Bait Matrices?

Oral bait tablets for wildlife rabies control are produced from a compressed mixture of fishmeal, wheat flour, paraffin wax, and coated vaccine granules. The matrix water activity is kept below 0.60 by drying at 25 °C in a forced-air dryer; water activity is measured by dew-point hygrometry according to ISO 18787. The vaccine component is a freeze-dried granulate incorporated at 5–10% w/w after fluidised-bed coating with hydrogenated vegetable oil melting in the range of 52–58 °C. Compression force is set to produce a breaking strength of 15–30 N, measured with a 10 mm stainless steel probe at 1.0 mm/s compression speed. Hardness above 30 N reduces puncture and chewing release in foxes and raccoon dogs, while hardness below 15 N generates excessive fine particles during aerial distribution. Heat-labile antigen granules are not processed in twin-screw extruders with L/D above 20:1 because local shear heating exceeds 30 °C and reduces infectivity titer.

Granules for aerial baiting are prepared by low-shear wet granulation in a planetary mixer at 18–22 °C. The wet mass is extruded through a 1.5 mm screen, spheronised at 600–800 rpm, and dried in a fluid-bed dryer with inlet air temperature not exceeding 25 °C. Higher inlet air temperatures cause lipid migration to the granule surface and form a hydrophobic film that delays antigen release. The dried premix is passed over a 1.0–2.0 mm sieve deck; fines below 1.0 mm are removed, because they are preferentially lost during fixed-wing bait drops and create dose variability. Release from the bait is not gastric dissolution; the compressed matrix must break immediately in the oral cavity to allow vaccine contact with the buccal and tonsillar mucosa. An enteric coating would therefore be contraindicated and is not used in oral rabies vaccine baits. Licensed live recombinant oral baits are released under strain-specific amplification protocols compatible with 9 CFR 113.312 and WOAH Terrestrial Manual Chapter 3.1.17.

For injectable lyophilized presentations, the antigen concentrate is diluted into a cryoprotectant solution containing sucrose and trehalose at a combined total solids of 5–7% w/v, glycine at 1–2% w/v, and phosphate buffer at 0.01–0.02 M prior to filling into vials. The solution is frozen to -45 °C at 0.5 °C/min; annealing at -20 °C for 2 h allows complete crystallisation of glycine and prevents vial cracking. Primary drying is executed with a product temperature not exceeding -25 °C and a chamber pressure of 50–100 mTorr (6.7–13.3 Pa); collapse is detected by comparative freeze-drying microscopy and product temperature probes placed in edge and centre vials. Secondary drying is ramped to 25 °C and held until residual moisture by Karl Fischer titration (USP <921> Method Ic) is below 3.0% w/w. Residual moisture above 3.0% w/w depresses the glass transition temperature of the dried cake below 25 °C, which permits molecular mobility and virus glycoprotein aggregation during storage.

The dried cake is reconstituted with sterile water for injection to a final dose volume of 1.0 mL; collapsed cakes yield visible granules with a reconstitution time greater than 120 s and are rejected. The reconstituted liquid is used immediately; if held for more than 2 h at 25 °C, the virus titer decreases by 0.2–0.5 log10 because of pH shift in the unbuffered diluent. Lyophilized powder used in capsule or bait granule production is milled and sieved under dry nitrogen with relative humidity below 10% RH; exposure to ambient relative humidity above 60% RH causes rapid water uptake into the amorphous cake and should be avoided. Residual moisture testing after milling is repeated because milling generates amorphous surfaces that are hygroscopic.

When Sachet Filling Lines Exceed 25°C for More Than 24 Hours, Blister Seal Integrity Cannot Be Guaranteed

Liquid bait inserts and oral solutions for sachet filling are prepared as a viscous suspension in 3–5 mL laminated foil-polyethylene blisters. The vehicle contains sucrose 30% w/v, glycerol 10% w/v, gelatin 1% w/v, and phosphate buffer 0.02 M adjusted to pH 7.2. Viscosity at 20 °C is maintained between 80–120 mPa·s to keep freeze-dried antigen particles uniformly dispersed during form-fill-seal operations; in-process control uses a Brookfield viscometer with spindle LV2 at 60 rpm. The fill is performed at 4±2 °C under nitrogen or argon headspace with residual oxygen below 2.0% v/v. Headspace oxygen is measured by electrochemical cell after destructive sampling.

Temperature excursions above 25 °C for more than 24 h cause differential expansion between the foil and polyethylene layers, increasing the leak rate above the release acceptance limit of 0.01 cm³/min under vacuum decay per ASTM F2338-09. Freeze-thaw is prohibited; a single cycle at -20 °C can reduce viral infectivity titer by 0.5–1.0 log10 TCID50/mL, with the greatest loss occurring in formulations containing 0.02 M phosphate alone because salt crystallisation damages the viral envelope. Sachets are therefore shipped in insulated containers with phase-change material at 2–8 °C and continuous temperature loggers.

Hard gelatin capsules are not a primary commercial rabies vaccine presentation for field use. Published data for capsule-based oral delivery of rabies antigen is limited to experimental bait-acceptance or efficacy studies in captive animals. When capsules are used, size 0 or 1 hard gelatin capsules are filled with freeze-dried powder diluted with mannitol to a total fill weight of 250–400 mg. The capsule body is perforated with a 1.0 mm needle to allow release in the oral cavity; intact capsules are swallowed and deliver the antigen to the stomach, where viral infectivity is rapidly lost at pH below 3.0 and pepsin activity. Because of this limitation, capsule use is rarely extended beyond comparator trials and is not recommended for regulatory oral bait licensing.

Aluminium Adjuvant Binding Efficiency and Thiomersal Partitioning in Multi-Dose Livestock Vials

In multi-dose livestock presentations for cattle, equine, and ovine use, the aluminium hydroxide adjuvant must maintain at least 85% antigen binding after 12 months at 2–8 °C. Binding efficiency is determined by ultracentrifugation of the finished product at 10 000 × g for 30 min followed by ELISA quantification of free antigen in the supernatant. Phosphate-buffered saline at molarity above 0.10 M displaces adsorbed glycoprotein from aluminium hydroxyphosphate binding sites and must be avoided; formulation phosphate is kept at 0.02 M or lower to prevent flocculation. The addition of thiomersal at 0.01% w/v partitions into the aqueous phase and does not significantly alter adjuvant adsorption in the presence of 1% w/v gelatin stabiliser.

Filling lines for multi-dose vials are equipped with magnetic stir bars or gentle recirculation loops; the bulk tank must be re-homogenised at 80–120 rpm before each filling campaign. The first and last filled vials from each lot are tested for aluminium content by atomic absorption spectrometry; the acceptable range is 90–110% of the label claim. Storage at 2–8 °C is required; exposure to -5 °C for 24 h causes gel particle growth above 10 µm, which can block 21-gauge needles. The unopened multi-dose vial after first broaching is used within 10 h when kept at 25 °C, consistent with field veterinary practice and antimicrobial effectiveness data.